Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Journavx (suzetrigine) is a first-in-class, non-opioid oral pain reliever, offering an alternative to opioid analgesics for the management of acute pain without the addiction risk associated with opioids.
Journavx is FDA-approved for the treatment of moderate to severe acute pain, including postoperative pain, in adults.
Suzetrigine selectively blocks the NaV1.8 voltage-gated sodium channel, which is expressed in peripheral sensory neurons, including dorsal root ganglion neurons, where it transmits pain signals. By selectively inhibiting NaV1.8, suzetrigine blocks pain signal transmission to the spinal cord and brain without acting on opioid receptors.
The recommended starting dose is 100 mg orally, taken on an empty stomach at least 1 hour before or 2 hours after food. Starting 12 hours after the initial dose, 50 mg is taken orally every 12 hours, with or without food. Journavx has not been studied beyond 14 days of use and should be used for the shortest duration consistent with treatment goals, as determined by the treating physician.
Journavx requires attention to several important drug interaction and population-specific considerations.
Concomitant use with strong CYP3A inhibitors is contraindicated, as it significantly increases drug exposure and adverse reaction risk. The dose must be reduced when used with moderate CYP3A inhibitors.
Suzetrigine induces CYP3A. Using Journavx with sensitive CYP3A substrate medications may require dose adjustment of those other medications when starting or stopping Journavx.
Patients on certain hormonal contraceptives (containing progestins other than levonorgestrel or norethindrone) should use additional non-hormonal contraception or switch to an alternative method during treatment and for 28 days after stopping Journavx.
Patients with moderate hepatic impairment require a lower dose. Journavx should be avoided in patients with severe hepatic impairment (Child-Pugh Class C).
Avoid grapefruit and grapefruit juice during treatment, as it can affect drug levels.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Journavx (suzetrigine) is manufactured by Vertex Pharmaceuticals, the first non-opioid pain medicine approved for moderate to severe acute pain.
Import of Journavx through a Named Patient Program requires a valid prescription from the treating physician, relevant clinical documentation regarding the acute pain condition, and supporting documentation as required by Indian regulatory authorities.
NPP sources Journavx directly from Vertex Pharmaceuticals' authorized supply chain to ensure product authenticity and regulatory compliance.
Journavx is sourced through verified, GDP-compliant channels from Vertex Pharmaceuticals' authorized supply chain to ensure authenticity and quality.
Journavx tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F).
Once sourced, Journavx is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Journavx through NPP's regulated import pathway, with pain management and surgical specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support postoperative and acute pain management coordination for Journavx access.
Delhi's major hospitals assist patients with prescription support and documentation for Journavx.
Bangalore's specialist network offers access to non-opioid pain management options for eligible patients.
Chennai-based specialists coordinate Journavx access alongside comprehensive perioperative care.
Hyderabad's care institutions support patients pursuing Journavx therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Journavx.
Pune-based specialists assist with prescription support and Journavx treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Journavx.
Kochi's specialist units assist patients with the documentation needed for Journavx access.
Chandigarh's care centers support Journavx treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Journavx access process.
Lucknow-based centers assist patients pursuing Journavx therapy.
Bhubaneswar's institutions support access to Journavx for eligible patients.
Guwahati's specialists help coordinate Journavx access for patients across the Northeast.
Patients in other cities across India can also access Journavx through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
